Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nivolumab alone, nivolumab + ipilimumab, or chemotherapy in MSI-H/dMMR metastatic colorectal cancer
NL-OMON56215Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Started Oct 2019; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON56215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56215.